Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron
Maximilian J. Mair, Manfred Mitterer, Pia Gattinger, et al.
Cancer Cell (2022) Vol. 40, Iss. 5, pp. 444-446
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin C. Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 88
Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies
Pia Gattinger, Anna Ohradanova‐Repic, Rudolf Valenta
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5352-5352
Open Access | Times Cited: 19
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
María Rescigno, Chiara Agrati, Carlo Salvarani, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer
Emanuele Vita, Federico Monaca, Luca Mastrantoni, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 273-273
Open Access
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer
Annika Fendler, Scott T.C. Shepherd, Lewis Au, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 10, pp. 100781-100781
Open Access | Times Cited: 22
SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants
David B. Reeg, Maike Hofmann, Christoph Neumann‐Haefelin, et al.
Pathogens (2023) Vol. 12, Iss. 2, pp. 244-244
Open Access | Times Cited: 14
mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer
No‐Joon Song, Karthik B. Chakravarthy, Hyeongseon Jeon, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e007922-e007922
Open Access | Times Cited: 4
SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
Laura Boekel, Yaëlle R Besten, Femke Hooijberg, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 11, pp. e747-e750
Open Access | Times Cited: 19
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases
Eileen W Stalman, Luuk Wieske, Koos P J van Dam, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 12, pp. 1757-1766
Open Access | Times Cited: 19
Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell®
Sevastyan O. Rabdano, Ellina Ruzanova, Iuliia V. Pletyukhina, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 874-874
Open Access | Times Cited: 11
COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future
Victoria Hall, Benjamin W. Teh
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_1, pp. S55-S69
Open Access | Times Cited: 11
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
Angioletta Lasagna, Federica Bergami, Daniele Lilleri, et al.
ESMO Open (2022) Vol. 7, Iss. 5, pp. 100574-100574
Open Access | Times Cited: 14
Safety and Immunogenicity of the Convacell® Recombinant N Protein COVID-19 Vaccine
Sevastyan O. Rabdano, Ellina Ruzanova, Denis Makarov, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 100-100
Open Access | Times Cited: 2
Ad5‐nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants
Weiya Kong, Qingyang Zhong, Mingxiao Chen, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 13
Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study
Fabrizio Nelli, Agnese Fabbri, Antonella Virtuoso, et al.
Current Oncology (2023) Vol. 30, Iss. 5, pp. 5103-5115
Open Access | Times Cited: 5
Updated COVID‐19 clearance time among patients with cancer in the Delta and Omicron waves
Zachary M. Avigan, Rodrigo Paredes, Leora Boussi, et al.
Cancer Medicine (2023) Vol. 12, Iss. 16, pp. 16869-16875
Open Access | Times Cited: 5
COVID-19 in Lung Transplant Recipients: A Report on 10 Recent Cases
Lea Reemann, Nikolaus Kneidinger, B Sczepanski, et al.
Viruses (2024) Vol. 16, Iss. 5, pp. 709-709
Open Access | Times Cited: 1
Prevalence and Outcomes of COVID-19 among Hematology/Oncology Patients and Providers of a Community-Facing Health System during the B1.1.529 (“Omicron”) SARS-CoV-2 Variant Wave
Samuel A. Kareff, Aliya Khan, Priscila Barreto‐Coelho, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4629-4629
Open Access | Times Cited: 6
Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 Variants After Fourth Vaccination or Tixagevimab and Cilgavimab Administration in Patients With Cancer
Maximilian J. Mair, Manfred Mitterer, Pia Gattinger, et al.
JAMA Oncology (2022) Vol. 8, Iss. 11, pp. 1694-1694
Open Access | Times Cited: 5
Use of remdesivir for COVID-19 in patients with hematologic cancer
Alexandra Martin‐Onraët, Corazón Barrientos-Flores, Diana Vilar‐Compte, et al.
Clinical and Experimental Medicine (2022) Vol. 23, Iss. 6, pp. 2231-2238
Open Access | Times Cited: 5
Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Andrés Chang, Akil Akhtar, Lilin Lai, et al.
Cancer Research Communications (2022) Vol. 2, Iss. 12, pp. 1684-1692
Open Access | Times Cited: 5
[Chinese consensus on severe acute respiratory syndrome coronavirus-2 vaccination in adult patients with hematological diseases (2023)].

PubMed (2023) Vol. 44, Iss. 1, pp. 19-25
Closed Access | Times Cited: 2
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines
Anna Maria Di Giacomo, Gianluca Giacobini, Gabriele Anichini, et al.
European Journal of Cancer (2022) Vol. 171, pp. 143-149
Open Access | Times Cited: 4
Inactivated Vaccine Dosage and Serum IgG Levels Correlate with Persistent COVID-19 Infection in Hematologic Malignancy Patients During the Omicron Surge in China
Ye Li, Ye Yang, Xuewu Zhang, et al.
Research Square (Research Square) (2024)
Open Access
N-protein vaccine Convacell® is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial
Sevastyan O. Rabdano, Ellina Ruzanova, Anastasiya Evgenievna Vertyachikh, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1 - Next Page

Scroll to top